Personalized exercise plan for cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm interventional study aimed at creating and implementing an institution-based exercise prescription protocol for cancer survivors. Participants undergo a comprehensive pre-exercise evaluation including medical history, cardiovascular risk assessment, functional fitness testing, CPET, and possibly musculoskeletal ultrasound. Based on these results, physiatrists classify participants into risk levels and design a tailored exercise program with aerobic, resistance, and flexibility components. Participants perform the prescribed regimen with weekly logs and safety monitoring to ensure safe progression and data feedback.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 to 80 years.
2. Cancer Cohorts: Pathologically confirmed diagnosis of AJCC TNM stage I-III, and having completed curative-intent treatment (including surgery ± adjuvant chemotherapy/radiotherapy, etc) for at least 2 months.
3. Cancer cohort must have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.
4. Ability to comply with weekly structured exercise training (3-4 professionally supervised sessions per week) and willingness to accept telephone follow-ups or report exercise status via exercise logs/wearable devices.
5. Self-reported failure to meet the following physical activity guidelines within the past 3 months: at least 150 minutes of moderate-intensity aerobic exercise per week OR at least 75 minutes of vigorous-intensity aerobic exercise per week; AND no regular resistance training (≥ 2 sessions per week) within the past 3 months.

Exclusion Criteria:

1. Cardiovascular instability: History of acute coronary syndrome (ACS), myocardial infarction (MI), acute exacerbation of heart failure, or hospitalization for heart failure within the past 3 months; unstable angina; uncontrolled arrhythmia; or uncontrolled hypertension (resting blood pressure \> 180/110 mmHg).
2. Hypoxemia: Resting oxygen saturation (SpO2) \< 90%.
3. Metabolic instability: Severe hypoglycemic event or diabetic ketoacidosis (DKA) within the past 3 months.
4. Musculoskeletal or neurological risks: Unstable bone metastasis or bone metastasis with a high risk of fracture; recent major fracture or orthopedic surgery where weight-bearing is not yet permitted; or other severe neuromuscular diseases that compromise the safety of exercise.
5. Hematological risks: Thrombocytopenia (Platelet count \< 50,000/μL), severe anemia (Hemoglobin \[Hb\] \< 8 g/dL), or neutropenia (Absolute Neutrophil Count \[ANC\] \< 1,000/μL).
6. Deemed unsuitable for exercise intervention as determined by clinical assessment from the attending physician or study investigator.
7. Concurrent participation in other formal exercise or weight-loss intervention programs.
8. Inability to comprehend or complete the informed consent form, or inability to comply with the study procedures.

Where it's running

• Kaohsiung Medical University Chung-Ho Memorial Hospital
  Kaohsiung, Taiwan, Taiwan Recruiting

Study contacts

• Study coordinator: Ko-Long Lin, PhD
• Email: klin967@gmail.com
• Phone: 886-978-862-831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen

  A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.

  Recruiting at 2 sites Varian, a Siemens Healthineers Company · St Louis, Missouri and 1 other locations · NCT07824583

• Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer

  This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07561567

• Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery

  This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.

  Recruiting Ondokuz Mayıs University · Samsun, Samsun · NCT07500376

• Radiation segmentectomy with Y-90 resin microspheres for liver tumors

  This will test whether injecting Y-90 resin microspheres into the tumor-bearing part of the liver is safe and can shrink tumors in adults with liver cancer.

  Recruiting at 9 sites Ankara University · Adana and 19 other locations · NCT07345247

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.